tetano
Editor, Senior Moderator
Nat Commun
. 2023 May 19;14(1):2810.
doi: 10.1038/s41467-023-38457-x. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
Mai Komori[SUP] #[/SUP][SUP] 1 [/SUP], Takuto Nogimori[SUP] #[/SUP][SUP] 2 [/SUP], Amber L Morey[SUP] 1 [/SUP], Takashi Sekida[SUP] 3 [/SUP], Keiko Ishimoto[SUP] 1 [/SUP], Matthew R Hassett[SUP] 1 [/SUP], Yuji Masuta[SUP] 2 [/SUP], Hirotaka Ode[SUP] 4 [/SUP], Tomokazu Tamura[SUP] 5 [/SUP], Rigel Suzuki[SUP] 5 [/SUP], Jeff Alexander[SUP] 1 [/SUP], Yasutoshi Kido[SUP] 6 [/SUP], Kenta Matsuda[SUP] 1 [/SUP], Takasuke Fukuhara[SUP] 5 [/SUP], Yasumasa Iwatani[SUP] 4 7 [/SUP], Takuya Yamamoto[SUP] 8 9 10 [/SUP], Jonathan F Smith[SUP] 11 [/SUP], Wataru Akahata[SUP] 12 [/SUP]
Affiliations
Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal signal sequence and a C-terminal transmembrane domain (RBD-TM). Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and B-cell responses in non-human primates (NHPs). In addition, immunized hamsters and NHPs are protected against SARS-CoV-2 challenge. Importantly, RBD-specific antibodies against VOCs are maintained for at least 12 months in NHPs. These findings suggest that this saRNA platform expressing RBD-TM will be a useful vaccine candidate inducing durable immunity against emerging SARS-CoV-2 strains.
. 2023 May 19;14(1):2810.
doi: 10.1038/s41467-023-38457-x. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
Mai Komori[SUP] #[/SUP][SUP] 1 [/SUP], Takuto Nogimori[SUP] #[/SUP][SUP] 2 [/SUP], Amber L Morey[SUP] 1 [/SUP], Takashi Sekida[SUP] 3 [/SUP], Keiko Ishimoto[SUP] 1 [/SUP], Matthew R Hassett[SUP] 1 [/SUP], Yuji Masuta[SUP] 2 [/SUP], Hirotaka Ode[SUP] 4 [/SUP], Tomokazu Tamura[SUP] 5 [/SUP], Rigel Suzuki[SUP] 5 [/SUP], Jeff Alexander[SUP] 1 [/SUP], Yasutoshi Kido[SUP] 6 [/SUP], Kenta Matsuda[SUP] 1 [/SUP], Takasuke Fukuhara[SUP] 5 [/SUP], Yasumasa Iwatani[SUP] 4 7 [/SUP], Takuya Yamamoto[SUP] 8 9 10 [/SUP], Jonathan F Smith[SUP] 11 [/SUP], Wataru Akahata[SUP] 12 [/SUP]
Affiliations
- PMID: 37208330
- PMCID: PMC10199074
- DOI: 10.1038/s41467-023-38457-x
Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal signal sequence and a C-terminal transmembrane domain (RBD-TM). Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and B-cell responses in non-human primates (NHPs). In addition, immunized hamsters and NHPs are protected against SARS-CoV-2 challenge. Importantly, RBD-specific antibodies against VOCs are maintained for at least 12 months in NHPs. These findings suggest that this saRNA platform expressing RBD-TM will be a useful vaccine candidate inducing durable immunity against emerging SARS-CoV-2 strains.